| |
* Trademark is the property of its owner.
|
|
 This study was designed to determine the safety of intracameral moxifloxacin 0.5%
(VIGAMOX® solution, Alcon, Fort Worth, Texas) in 65 eyes undergoing cataract surgery. The average patient age was 69.5. Patients received an intracameral injection of 0.1 mL VIGAMOX® solution 0.5% through a 27-gauge cannula at the end of the case.
This slide shows that the mean decrease in endothelial cell density pre-op compared to endothelial cell density post-op is 70, which was not statistically significant. Further, anterior chamber cell and flare were seen only at day one post-op. Intracameral VIGAMOX® solution 0.5% appears to be non-toxic in terms of visual rehabilitation, anterior chamber cell/flare, and endothelial cell density.1 |
